AcquisitionOther
Coherus BioSciences, Inc. acquired Surface Oncology
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Coherus BioSciences, Inc. -> Surface Oncology · $20
The Surface acquisition adds two differentiated clinical stage assets to Coherus novel I-O pipeline: SRF388, a novel IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted anti
Open source record (SEC) ↗